Abstract:Background We constructed a new proteomic aging clock (PAC) and computed the published Lehallier PAC to estimate biological age. We tested the associations of PACs with mortality in longer-term cancer survivors and cancer-free participants. Methods ARIC measured 4,712 proteins using SomaScan in plasma samples collected at multiple visits, including Visit 5 (2011-13), from 806 cancer survivors and 3,699 cancer-free participants (aged 66-90). In the training set (N=2,466 randomly selected cancer-free participants), we developed the new PAC using elastic net regression and computed Lehallier PAC. Age acceleration was calculated as residuals after regressing each PAC on chronological age after excluding the training set. We used multivariable-adjusted Cox proportional hazards regression to examine the associations of age acceleration with all-cause, cardiovascular disease (CVD), and cancer mortality. Results Both PACs were correlated with chronological age [r=0.70-0.75]. Age acceleration for these two PACs was similarly associated with all-cause mortality in cancer survivors [hazard ratios (HRs) per 1 SD=1.40-1.42, p<0.01]. The associations with all-cause mortality were similar in cancer survivors and cancer-free participants for both PACs [p-interactions=0.20-0.62]. There were also associations with all-cause mortality in breast cancer survivors for both PACs [HRs=1.54-1.72, p<0.01] and colorectal cancer survivors for the new PAC [HR=1.96, p=0.03]. Additionally, the new PAC was associated with cancer mortality in all cancer survivors. Finally, HRs=1.42-1.61 [p<0.01] for CVD mortality in cancer-free participants for two PACs but the association was insignificant in cancer survivors perhaps due to a limited number of outcomes. Conclusion PACs hold promise as potential biomarkers for premature mortality in cancer survivors.

What problem does this paper attempt to address?

This paper mainly explores the relationship between Proteomic Aging Clocks (PAC) and long-term cancer survivors, as well as the mortality rate of individuals without cancer. The research team used SomaScan technology to measure 4712 proteins in the "Atherosclerosis Risk in Communities" (ARIC) study to construct a new PAC and calculate the PAC proposed by Lehallier et al. The study found that both types of PAC (the newly developed and Lehallier's) were highly correlated with chronological age and associated with all-cause mortality. In cancer survivors and participants without cancer, the age acceleration of both PACs (i.e. the difference between biological age and chronological age) had similar associations with all-cause mortality. In addition, the new PAC was associated with all-cause mortality in breast cancer and colorectal cancer survivors, as well as cancer-specific mortality in all cancer survivors. However, the association between Lehallier's PAC and cancer-specific mortality in cancer survivors was not significant, possibly due to limited sample size. The paper also mentioned that PAC could serve as a potential biomarker for predicting premature mortality in cancer survivors. Limitations of the study include the difference in time between cancer survivor diagnoses and blood collection, limited number of events, and lack of detailed cancer treatment information, among others. Future research needs to validate these findings in larger populations of cancer survivors. In conclusion, this paper aims to address how to assess the biological age of cancer survivors and predict their mortality risk through PAC, providing potential biomarkers for clinical practice.

Proteomic Aging Clocks and the Risk of Mortality among Longer-Term Cancer Survivors in the Atherosclerosis Risk in Communities (ARIC) Study